A new discovery, a chimeric protein designed laboratory by researchers of Novartis in Siena in collaboration with colleagues at the University of Florence, could eventually lead to the development of vaccine an effective against meningitis from meningococcal type B. the research findings were published in the latest issue of the journal Science Transaltional Medicine.
The protein, derived on the basis of information obtained directly from the bacterium, was achieved with the technique of revers vaccinology and could pave the way to equally important as that vaccination of malaria, that related to colds by rhinoviruses and all those bacterial infections and viral that currently do not have a precise and antagonist which change continuously.
This approach involves genomic sequence "encoding" of meningococcal and the resulting "selection" of proteins that are most likely to have characteristics that make it effective to attack it and possible inside of a vaccine.
Specifically, in this case, researchers studying genome the were able to identify a specific protein, FHBP, fatcor B binding protein, with a particular value: to stimulate a very strong response from the immune system. The grandeur of the discovery was not only the protein isolate, but also be able to sequenziarla in 2000 different meningococcal b strains.
One of the biggest problems for which a development of an effective vaccine was not never happened, was just the log differences and the resulting different antigenic variants. Researchers have taken the most widespread and common and have developed a vaccine that is about to conclude the "bureaucracy" of its existence. How do you explain Rino Rappuoli, Coordinator of the experiment:
Genomics offers increasing potential and thanks to it we were able to develop highly innovative strategies in the search for new vaccines. The study describes laboratory activity still in the initial phase and it will take years to develop a new vaccine, but the results achieved represent a crucial step towards the development of new vaccines that can protect against pathogens are highly variable.
The protein, derived on the basis of information obtained directly from the bacterium, was achieved with the technique of revers vaccinology and could pave the way to equally important as that vaccination of malaria, that related to colds by rhinoviruses and all those bacterial infections and viral that currently do not have a precise and antagonist which change continuously.
This approach involves genomic sequence "encoding" of meningococcal and the resulting "selection" of proteins that are most likely to have characteristics that make it effective to attack it and possible inside of a vaccine.
Specifically, in this case, researchers studying genome the were able to identify a specific protein, FHBP, fatcor B binding protein, with a particular value: to stimulate a very strong response from the immune system. The grandeur of the discovery was not only the protein isolate, but also be able to sequenziarla in 2000 different meningococcal b strains.
One of the biggest problems for which a development of an effective vaccine was not never happened, was just the log differences and the resulting different antigenic variants. Researchers have taken the most widespread and common and have developed a vaccine that is about to conclude the "bureaucracy" of its existence. How do you explain Rino Rappuoli, Coordinator of the experiment:
Genomics offers increasing potential and thanks to it we were able to develop highly innovative strategies in the search for new vaccines. The study describes laboratory activity still in the initial phase and it will take years to develop a new vaccine, but the results achieved represent a crucial step towards the development of new vaccines that can protect against pathogens are highly variable.
0 comments:
Post a Comment